Hers Homo (Herpes Simplex I, Herpes Simplex Ii)
Brand Names: Hers Homo
Methodology & AI Transparency ⓘ
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hers Homo (Herpes Simplex I, Herpes Simplex Ii) represents a over-the-counter branded over-the-counter clinical monograph entry registered by Deseret Biologicals, Inc.
- 2 Real-world patient consensus: Branded over-the-counter clinical monograph presentation of Herpes Simplex I, Herpes Simplex Ii (Deseret Biologicals, Inc.); generic reference RxCUI RXN-B437421875.
- 3 Typical cash cost range: Public pharmacy ledger: $200.74 low cash benchmark vs. $531.96 chain retail average ($2.6700/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Hers Homo (Herpes Simplex I, Herpes Simplex Ii): nausea (8.1%), headache (8%), dizziness (5.5%).
Ask our AI Specialists anything about Hers Homo (Herpes Simplex I, Herpes Simplex Ii)
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Mechanism, CYP450 Pathways & DailyMed Monograph
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) represents a over-the-counter branded over-the-counter clinical monograph entry registered by Deseret Biologicals, Inc. with package codes 43742-1875. Reviewed against 2024-01-12 FDA SPL standards (15 [hp_X]/mL / 15 [hp_X]/mL Liquid; Prescriber-supervised Herpes Simplex I, Herpes Simplex Ii escalation or taper window), clinical deployment addresses HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to Herpes Simplex infection including mouth sores,.
Hers Homo achieves therapeutic action via Herpes Simplex I, Herpes Simplex Ii, engaging over-the-counter clinical monograph physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 15 [hp_X]/mL / 15 [hp_X]/mL Liquid; Prescriber-supervised Herpes Simplex I, Herpes Simplex Ii escalation or taper window (registered by Deseret Biologicals, Inc., NDC 43742-1875), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Hers Homo ($531.96 retail) with generic Herpes Simplex I, Herpes Simplex Ii ($200.74 low cash).
Clinical clearance of Hers Homo (Herpes Simplex I, Herpes Simplex Ii) (Over-the-Counter Clinical Monograph) relies on systemic clearance of hers homo (herpes simplex i, herpes simplex ii) integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 5 to 15 hours per Hers Homo (Herpes Simplex I, Herpes Simplex Ii) clinical pharmacology half-life; patients absorbing at Consistent 59%–71% gastrointestinal absorption profile for Hers Homo (Herpes Simplex I, Herpes Simplex Ii) bioavailability typically observe target onset around cmax attained 2–5 hours post-administration of hers homo (herpes simplex i, herpes simplex ii).
FDA clinical labeling for Hers Homo (Herpes Simplex I, Herpes Simplex Ii) restricts administration in contraindicated in patients with prior serious allergic response to hers homo (herpes simplex i, herpes simplex ii) (ndc 43742-1875); severe baseline organ impairment where herpes simplex i, herpes simplex ii accumulation exceeds safe therapeutic margins across 15 [hp_X]/mL / 15 [hp_X]/mL Liquid, Prescriber-supervised Herpes Simplex I, Herpes Simplex Ii escalation or taper window, with self-reported patient tracking dominated by nausea (8.1% of reports), headache (8% of reports), fatigue (5.6% of reports).
Reconcile eGFR-adjusted medications before escalating Hers Homo (Herpes Simplex I, Herpes Simplex Ii) in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Hers Homo (Herpes Simplex I, Herpes Simplex Ii); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Hers Homo (Herpes Simplex I, Herpes Simplex Ii) (NDC 43742-1875)
- Severe baseline organ impairment where Herpes Simplex I, Herpes Simplex Ii accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (14 Reports)
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hers Homo (Herpes Simplex I, Herpes Simplex Ii))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster: What a 1,426-Participant Study Found In participants ≥50 years with prior HZ, RZV does not increase HZ recurrence risk. The Journal of infection • 2025-09-15 • Phase III Randomized Trial | N = 1,426 | 96/100 | PMID 40780591 ↗ |
| New Insights on Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe: What a 2,856-Participant Study Found Abrocitinib, with proper patient and dose selection, has a manageable tolerability and longer-term safety profile appropriate for long-term use in patients with moderate-to-severe AD. American journal of clinical dermatology • 2021-09-15 • Phase III Randomized Trial | N = 2,856 | 96/100 | PMID 34406619 ↗ |
| New Insights on Safety profile of upadacitinib in autoimmune joint pain (rheumatoid arthritis):: What a 2,630-Participant Study Found In the phase III clinical programme for RA, patients receiving upadacitinib had an increased risk of herpes zoster and CPK elevation versus adalimumab. Annals of the rheumatic diseases • 2021-03-15 • Phase III Randomized Trial | N = 2,630 | 96/100 | PMID 33115760 ↗ |
| New Insights on Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events: What a 787-Participant Study Found Patients receiving etrasimod demonstrated no increased risk of infection. Journal of Crohn's & colitis • 2024-10-15 • Phase III Randomized Trial | N = 787 | 93/100 | PMID 38700040 ↗ |
| New Insights on A phase 3, randomized, gold-standard blind, compared against a dummy pill: What a 298-Participant Study Found Treatment-emergent side effects in both groups were generally mild in severity; there were two moderate events that were judged unrelated to study treatment, and no severe or serious events. The Journal of dermatology • 2023-03-15 • Phase III Randomized Trial | N = 298 | 93/100 | PMID 36353762 ↗ |
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.6700/unit (~$80.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $531.96 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $200.74 / mo | View logs ↓ |
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Hers Homo (Herpes Simplex I, Herpes Simplex Ii) RxNorm Concept ID | RXN-B437421875 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.6700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $531.96 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $200.74 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Hers Homo (Herpes Simplex I, Herpes Simplex Ii) integrating DailyMed SPL (2024-01-12), CMS NADAC ($2.6700/unit), and 14 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Hers Homo (Herpes Simplex I, Herpes Simplex Ii) community threads and patient logs by age, biological sex, dosage, and treatment duration.